SLXN Initiates Phase 2/3 Trial
Silexion Therapeutics receives approval from Germany's BfArM to initiate Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer
SLXN - Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer